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BACKGROUND Intra-aortic balloon pump (IABP) therapy is a widely
used intervention for acute myocardial infarction with shock. Guide-
lines, which previously strongly recommended it, have recently un-
dergone substantial change.We sought to synthesize all available study
evidence on the use of IABP therapy in acute myocardial infarction.
METHODS We performed a meta-analysis of all randomized and
observational trials. To assess the baseline inequality between treat-
ment and control groups in observational studies, and its relationship
with apparent beneﬁt, we devised a simple baseline inequality index.
We then performed a random-effects meta-regression to assess mor-
tality adjusted for the baseline risk.
RESULTS There were 12 eligible RCTs randomizing 2,123 patients. In
the RCTs, IABP had no statistically signiﬁcant effect on mortality,
odds ratio (OR) 0.96, 95% conﬁdence interval (CI) 0.74 to 1.24, with no
signiﬁcant heterogeneity between trials (I2¼0%, p¼0.52). This result
was consistent even when studies were stratiﬁed by the presence or
absence of shock: OR in those with shock 0.94 (95% CI 0.69 to 1.28,
p¼0.69 , I2¼0%), OR in those without shock 0.98 (95% CI 0.57 to 1.69,
p¼0.95, I2¼17%). There were 15 eligible observational studies totaling
15,530 patients. Their results were extensively mutually conﬂicting
(heterogeneity I2¼97%, p<0.001), causing wide uncertainty in the
summary estimate for the association with mortality (OR 0.96, CI 0.54
to 1.70). A simple index of baseline risk marker imbalance in the
observational studies appeared to explain much of the heterogeneity
in the observational data (R2meta¼46.2%, p<0.001).CONCLUSIONS IABP therapy was not found to improve mortality among
patients with AMI in the RCTs, regardless of whether patients had cardio-
genic shock or not. The observational studies showed a variety ofmutually
contradictory associations between IABP therapy and mortality, much of
which was explained by the differences between studies in the balance of
risk factors between IABP and non-IABP groups.
CATEGORIES CORONARY: Acute Myocardial Infarction
TCT-262
Thrombus aspiration does not reduce mortality in STEMI patients: a meta-
analysis of 20,192 patients, with implications for future trial design
Yousif Ahmad,1 Sayan Sen,1 Daniel Keene,2 Christopher Cook,3
Sukhjinder S. Nijjer,4 Ricardo Petraco,5 Judith Finegold,4
Matthew Shun-Shin,1 Graham Cole,1 Iqbal S. Malik,6
Christopher S. Baker,7 Michael Bellamy,7 Rafﬁ R. Kaprielian,7
Ghada Mikhail,8 Justin E. Davies,1 Jamil Mayet,1 Darrel P. Francis1
1Imperial College London, London, United Kingdom; 2Imperial College,
London, London, London; 3Imperial College London, London, VA;
4Imperial College London, London, London; 5Imperial College,
London, United Kingdom; 6Imperial College NHS Trust, London,
London; 7Imperial College Healthcare NHS Trust, London, United
Kingdom; 8Imperial College Healthcare Trust, London, United
Kingdom
BACKGROUND Thrombus aspiration is a mechanistically logical
adjunct in primary angioplasty for acute myocardial infarction. Indi-
vidual randomized controlled trials (RCTs) have not shown a
consensus of mortality reduction and there are concerns about stroke.
We perform a meta-analysis of all available RCT data on thrombus
aspiration, including the large, recently published TOTAL trial.
METHODS A meta-analysis of RCTs of thrombus aspiration, including
the recent TOTAL data was performed. The primary efﬁcacy endpoint
was mortality, and the primary safety endpoint was stroke. Outcomes
were assessed both at the short-term (30-days) and longer-term (6-12
months) timepoints. We then consider the number of patients that
would be required to adequately power a trial for a new therapy in
STEMI, considering the control arm mortality observed in contem-
porary randomized trials.
RESULTS At 30 days (11 trials; 20,192 patients) there was a marginally
non-signiﬁcant reduction in all cause-mortality with thrombus aspi-
ration (OR 0.844, 95% CI 0.710-1.003, p¼0.05). The longer-term
follow-up data (13 trials; 20,142 patients) was similarly non-signiﬁcant
(OR 0.89, 95% CI 0.78-1.01, p¼0.08). At both 30 days and longer-term
follow-up, there was a statistically signiﬁcant increase in stroke with
thrombus aspiration (OR 1.56, 95% CI 1.05 to 2.32, p¼0.03, and OR
1.94, 95% CI 1.24 to 3.04, p¼0.04 respectively). The mortality of
STEMI in control arms of trials is 3.0%. To reliably detect a statistically
signiﬁcant 10% relative risk reduction in STEMI mortality from 3.0%
to 2.7% would require almost 100,000 patients.
